{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:27:24Z","timestamp":1777552044668,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10741-019-09849-3","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T15:03:04Z","timestamp":1565708584000},"page":"899-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Minireview: are SGLT2 inhibitors heart savers in diabetes?"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1932","authenticated-orcid":false,"given":"Petra","family":"Grubi\u0107 Rotkvi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Cigrovski Berkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Bulj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"Rotkvi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"9849_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jacc.2018.01.047","volume":"71","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J (2018) Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes. J Am Coll Cardiol 71:1379\u20131390","journal-title":"J Am Coll Cardiol"},{"key":"9849_CR2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"9849_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"issue":"4","key":"9849_CR4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"9","key":"9849_CR5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","volume":"2","author":"S Verma","year":"2017","unstructured":"Verma S, McMurray JJV, Cherney DZI (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2(9):939\u2013940","journal-title":"JAMA Cardiol"},{"issue":"6S","key":"9849_CR6","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.amjmed.2017.04.009","volume":"130","author":"B Staels","year":"2017","unstructured":"Staels B (2017) Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Med 130(6S):S30\u2013S39","journal-title":"Am J Med"},{"issue":"4","key":"9849_CR7","first-page":"347","volume":"2","author":"NJ Byrne","year":"2017","unstructured":"Byrne NJ, Parajuli N, Levasseur JL et al (2017) Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC: Basic Translational Sci 2(4):347\u2013354","journal-title":"JACC: Basic Translational Sci"},{"issue":"10","key":"9849_CR8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61(10):2108\u20132117","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"9849_CR9","first-page":"S1","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) Standards of medical care in diabetes-2018. Diabetes Care 41(Suppl.1):S1\u2013S2","journal-title":"Diabetes Care"},{"issue":"3","key":"9849_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"42","author":"K Huynh","year":"2014","unstructured":"Huynh K, Bernardo BC, McMullen JR, Ritchie RH (2014) Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacology Ther 42(3):375\u2013415","journal-title":"Pharmacology Ther"},{"issue":"4","key":"9849_CR11","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/EJE-17-0724","volume":"178","author":"E Levelt","year":"2018","unstructured":"Levelt E, Gulsin G, Neubauer S, McCann GP (2018) Mechanisms in endocrinology: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol 178(4):R127\u2013R139","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9849_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10741-012-9313-3","volume":"18","author":"M Takayuki","year":"2013","unstructured":"Takayuki M, Satoshi Y, Hidemichi K, Tetsuji M (2013) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18(2):149\u2013166","journal-title":"Heart Fail Rev"},{"issue":"1","key":"9849_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","volume":"17","author":"S Lahnwong","year":"2018","unstructured":"Lahnwong S, Chattipakorn SC, Chattipakorn N (2018) Potential mechanisms responsible for cardioprotective efects of sodium\u2013glucose co-transporter 2 inhibitors. Cardiovasc Diabetol 17(1):101","journal-title":"Cardiovasc Diabetol"},{"issue":"10166","key":"9849_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339","journal-title":"Lancet"},{"issue":"5","key":"9849_CR15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/1741826711417759","volume":"19","author":"G Ciof","year":"2012","unstructured":"Ciof G, Giorda CB, Chinali M et al (2012) Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Eur J Prev Cardiol 19(5):935\u2013943","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"9849_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.diabres.2013.07.004","volume":"101","author":"G Faden","year":"2013","unstructured":"Faden G, Faganello G, De Feo S et al (2013) The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract 101(3):309\u2013316","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"9849_CR17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren \u00d6, Johansson L, Wilding J, Langkilde AM, Sj\u00f6str\u00f6m CD, Sugg J, Parikh S (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16(2):159\u2013169","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"9849_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2015.10.013","volume":"30","author":"RA DeFronzo","year":"2016","unstructured":"DeFronzo RA (2016) The EMPA-REG study: what has it told to us? J Diabetes Complicat 30(1):1\u20132","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"9849_CR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","volume":"65","author":"M Kern","year":"2016","unstructured":"Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M (2016) The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin. Metabolism 65(2):114\u2013123","journal-title":"Metabolism"},{"key":"9849_CR20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3810\/pgm.2013.05.2667","volume":"125","author":"A Ptaszynska","year":"2013","unstructured":"Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J (2013) Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 125:181\u2013189","journal-title":"Postgrad Med"},{"key":"9849_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/hrt.2006.090845","volume":"93","author":"MM Kittleson","year":"2007","unstructured":"Kittleson MM, St. John ME, Bead V et al (2007) Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independentely of B-type natriuretic peptide levels. Heart 93:365\u2013367","journal-title":"Heart"},{"issue":"17","key":"9849_CR22","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359(17):1811\u20131821","journal-title":"N Engl J Med"},{"key":"9849_CR23","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.0000066420.36123.35","volume":"107","author":"JM Hare","year":"2003","unstructured":"Hare JM, Johnson RJ (2003) Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 107:1951\u20131953","journal-title":"Circulation"},{"key":"9849_CR24","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.12475","volume":"171","author":"N Fillmore","year":"2014","unstructured":"Fillmore N, Mori J, Lopaschuk GD (2014) Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 171:2080\u20132090","journal-title":"Br J Pharmacol"},{"key":"9849_CR25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39:1115\u20131122","journal-title":"Diabetes Care"},{"key":"9849_CR26","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","volume":"39","author":"G Daniele","year":"2016","unstructured":"Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M (2016) Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39:2036\u20132041","journal-title":"Diabetes Care"},{"key":"9849_CR27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2013.09.002","volume":"25","author":"JC Newman","year":"2014","unstructured":"Newman JC, Verdin E (2014) Ketone bodies as signaling metabolites. Trends Endocrinol Metab 25:42\u201352","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"9849_CR28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diabres.2014.08.009","volume":"106","author":"JC Newman","year":"2014","unstructured":"Newman JC, Verdin E (2014) Beta-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract 106(2):173\u2013181","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"9849_CR29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.expneurol.2007.12.029","volume":"211","author":"ML Haces","year":"2008","unstructured":"Haces ML, Hernandez-Fonseca K, Medina-Campos ON, Montiel T, Pedraza-Chaverri J, Massieu L (2008) Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions. Exp Neurol 211(1):85\u201396","journal-title":"Exp Neurol"},{"issue":"11","key":"9849_CR30","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/dom.13488","volume":"20","author":"F Prattichizzo","year":"2018","unstructured":"Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A (2018) Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab 20(11):2515\u20132522","journal-title":"Diabetes Obes Metab"},{"issue":"05","key":"9849_CR31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/a-0748-5745","volume":"69","author":"E Kutoh","year":"2019","unstructured":"Kutoh E, Hayashi J (2019) Effect of canagliflozin on heart function involving ketone bodies in patients with type 2 diabetes. Drug Res (Stuttg) 69(05):297\u2013300","journal-title":"Drug Res (Stuttg)"},{"key":"9849_CR32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA (2016) SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPAREG OUTCOME study. Diabetes Care 39:717\u2013725","journal-title":"Diabetes Care"},{"issue":"5","key":"9849_CR33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","volume":"71","author":"M Sano","year":"2018","unstructured":"Sano M (2018) A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol 71(5):471\u2013476","journal-title":"J Cardiol"},{"key":"9849_CR34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499\u2013508","journal-title":"J Clin Invest"},{"key":"9849_CR35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1210\/en.2011-1979","volume":"153","author":"BJ Jones","year":"2012","unstructured":"Jones BJ, Tan T, Bloom SR (2012) Minireview: glucagon in stress and energy homeostasis. Endocrinology 153:1049\u20131054","journal-title":"Endocrinology"},{"key":"9849_CR36","first-page":"638","volume":"63","author":"TJ Regan","year":"1964","unstructured":"Regan TJ, Lehan PH, Henneman DH, Behar A, Hellems HK (1964) Myocardial, metabolic and contractile response to glucagon and epinephrine. J Lab Clin Med 63:638\u2013664","journal-title":"J Lab Clin Med"},{"key":"9849_CR37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-016-0440-3","volume":"15","author":"A Ceriello","year":"2016","unstructured":"Ceriello A, Genovese S, Mannucci E, Gronda E (2016) Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol 15:123","journal-title":"Cardiovasc Diabetol"},{"key":"9849_CR38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","volume":"86","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86:1057\u20131058","journal-title":"Kidney Int"},{"key":"9849_CR39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853\u2013862","journal-title":"Diabetes Obes Metab"},{"key":"9849_CR40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 129:587\u2013597","journal-title":"Circulation."},{"key":"9849_CR41","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","volume":"2","author":"M Packer","year":"2017","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Zannad F (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2:1025\u20131029","journal-title":"JAMA Cardiol"},{"key":"9849_CR42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, Wust RC et al (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia 60:568\u2013573","journal-title":"Diabetologia"},{"key":"9849_CR43","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.109.914911","volume":"121","author":"M Kohlhaas","year":"2010","unstructured":"Kohlhaas M, Liu T, Knopp A, Zeller T, Ong MF, B\u00f6hm M, O'Rourke B, Maack C (2010) Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation 121:1606\u20131613","journal-title":"Circulation"},{"key":"9849_CR44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0008-6363(02)00809-X","volume":"57","author":"A Baartscheer","year":"2003","unstructured":"Baartscheer A, Schumacher CA, Borren MM, Belterman CN, Coronel R, Fiolet JW (2003) Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57:1015\u20131024","journal-title":"Cardiovasc Res"},{"issue":"5","key":"9849_CR45","doi-asserted-by":"crossref","first-page":"H2031","DOI":"10.1152\/ajpheart.01058.2004","volume":"288","author":"DC Lau","year":"2005","unstructured":"Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S (2005) Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288(5):H2031\u2013H2041","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9849_CR46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10741-017-9644-1","volume":"22","author":"VB Patel","year":"2017","unstructured":"Patel VB, Shah S, Verma S, Oudit GY (2017) Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev 22:889\u2013902","journal-title":"Heart Fail Rev"},{"key":"9849_CR47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","volume":"85","author":"W Timothy Garvey","year":"2018","unstructured":"Timothy Garvey W, Van Gaal L, Leiter LA et al (2018) Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 85:32\u201337","journal-title":"Metabolism"},{"issue":"1","key":"9849_CR48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M (2018) The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 17(1):6","journal-title":"Cardiovasc Diabetol"},{"key":"9849_CR49","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752\u2013772","journal-title":"Circulation"},{"issue":"10","key":"9849_CR50","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/dme.13424","volume":"34","author":"T Sato","year":"2017","unstructured":"Sato T, Miki T, Ohnishi H, Yamashita T, Takada A, Yano T, Tanno M, Tsuchida A, Miura T (2017) Effect of sodium\u2013glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with type 2 diabetes. Diabet Med 34(10):1367\u20131371","journal-title":"Diabet Med"},{"issue":"1","key":"9849_CR51","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","volume":"16","author":"A Natali","year":"2017","unstructured":"Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V (2017) Impact of empagliflozin on subclinical left ventricular dysfunction and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Dabet 16(1):130","journal-title":"Cardiovasc Dabet"},{"issue":"3","key":"9849_CR52","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D (2018) Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol 71(3):339\u2013351","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"9849_CR53","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/dom.13247","volume":"20","author":"MPA Baldassarre","year":"2018","unstructured":"Baldassarre MPA, Andersen A, Consoli A, Knop FK, Vilsboll T (2018) Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes Obes Metab 20(6):1350\u20131360","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"9849_CR54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1373\/clinchem.2011.165720","volume":"58","author":"RR van Kimmenade","year":"2012","unstructured":"van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58(1):127\u2013138","journal-title":"Clin Chem"},{"key":"9849_CR55","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","volume":"358","author":"E Braunwald","year":"2008","unstructured":"Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148\u20132159","journal-title":"N Engl J Med"},{"issue":"2","key":"9849_CR56","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","volume":"34","author":"H Tanaka","year":"2017","unstructured":"Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, Arakawa K, Togo M, Inagaki N, Kaku K (2017) Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther 34(2):436\u2013451","journal-title":"Adv Ther"},{"issue":"6","key":"9849_CR57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/jcm8060779","volume":"8","author":"MK Eickhoff","year":"2019","unstructured":"Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Moller M, Jorgensen NR, Faber J et al (2019) Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J Clin Med 8(6):779","journal-title":"J Clin Med"},{"issue":"6","key":"9849_CR58","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"JL Januzzi","year":"2017","unstructured":"Januzzi JL, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ (2017) Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol 70(6):704\u2013712","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"9849_CR59","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.peptides.2003.07.030","volume":"24","author":"MP Majowicz","year":"2003","unstructured":"Majowicz MP, Gonzalez Bosc LV, Albertoni Borghese MF, Delgado MF, Ortiz MC, Sterin Speziale N, Vidal NA (2003) Atrial natriuretic peptide and endothelin-3 target renal sodium-glucose cotransporter. Peptides 24(12):1971\u20131976","journal-title":"Peptides"},{"issue":"2","key":"9849_CR60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","volume":"130","author":"M Volpe","year":"2016","unstructured":"Volpe M, Carnovali M, Mastromarino V (2016) The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci 130(2):57\u201377","journal-title":"Clin Sci"},{"issue":"6","key":"9849_CR61","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","volume":"44","author":"F Bonnet","year":"2018","unstructured":"Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential diabetes complications and cardiovascular disease. Diabetes Metab 44(6):457\u2013464","journal-title":"Diabetes Metab"},{"issue":"1","key":"9849_CR62","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.redox.2013.07.006","volume":"1","author":"E Ho","year":"2013","unstructured":"Ho E, Galougahi KK, Liu CC, Bhindi R, Figtree GA (2013) Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol 1(1):483\u2013491","journal-title":"Redox Biol"},{"key":"9849_CR63","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1253\/circj.CJ-15-0012","volume":"79","author":"M Enomoto","year":"2015","unstructured":"Enomoto M, Ishizu T, Seo Y, Yamamoto M, Suzuki H, Shimano H, Kawakami Y, Aonuma K (2015) Subendocardial systolic dysfunction in asymptomatic normotensive diabetic patients. Circ J 79:1749\u20131755","journal-title":"Circ J"},{"key":"9849_CR64","unstructured":"https:\/\/clinicaltrials.gov\/\n                  \n                 Accessed 5 July 2019"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09849-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09849-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09849-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T20:13:25Z","timestamp":1602965605000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09849-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["9849"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09849-3","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"13 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}